ERX1595244 E-MTAB-4921:MEM001_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242711 SAMEA4071601 MEM001_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 1 dose ERX1595245 E-MTAB-4921:MEM002_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242712 SAMEA4071602 MEM002_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 2 dose ERX1595246 E-MTAB-4921:MEM005_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242713 SAMEA4071603 MEM005_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 3 dose ERX1595247 E-MTAB-4921:MEM007_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242714 SAMEA4071604 MEM007_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 4 dose ERX1595248 E-MTAB-4921:MEM009_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242715 SAMEA4071605 MEM009_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 5 dose ERX1595249 E-MTAB-4921:MEM011_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242716 SAMEA4071606 MEM011_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 6 dose ERX1595250 E-MTAB-4921:MEM011_N1_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242717 SAMEA4071607 MEM011_N1_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: normal disease Experimental Factor: 7 dose ERX1595251 E-MTAB-4921:MEM012_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242718 SAMEA4071608 MEM012_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 8 dose ERX1595252 E-MTAB-4921:MEM012_N1_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242719 SAMEA4071609 MEM012_N1_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: normal disease Experimental Factor: 9 dose ERX1595253 E-MTAB-4921:MEM013_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242720 SAMEA4071610 MEM013_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 10 dose ERX1595254 E-MTAB-4921:MEM013_N1_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242721 SAMEA4071611 MEM013_N1_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: normal disease Experimental Factor: 11 dose ERX1595255 E-MTAB-4921:MEM014_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242722 SAMEA4071612 MEM014_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 12 dose ERX1595256 E-MTAB-4921:MEM015_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242723 SAMEA4071613 MEM015_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 13 dose ERX1595257 E-MTAB-4921:MEM016_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242724 SAMEA4071614 MEM016_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 14 dose ERX1595258 E-MTAB-4921:MEM017_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242725 SAMEA4071615 MEM017_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 15 dose ERX1595259 E-MTAB-4921:MEM018_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242726 SAMEA4071616 MEM018_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 16 dose ERX1595260 E-MTAB-4921:MEM019_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242727 SAMEA4071617 MEM019_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 17 dose ERX1595261 E-MTAB-4921:MEM021_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242728 SAMEA4071618 MEM021_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 18 dose ERX1595262 E-MTAB-4921:MEM022_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242729 SAMEA4071619 MEM022_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 19 dose ERX1595263 E-MTAB-4921:MEM023_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242730 SAMEA4071620 MEM023_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 20 dose ERX1595264 E-MTAB-4921:MEM024_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242731 SAMEA4071621 MEM024_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 21 dose ERX1595265 E-MTAB-4921:MEM025_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242732 SAMEA4071622 MEM025_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 22 dose ERX1595266 E-MTAB-4921:MEM026_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242733 SAMEA4071623 MEM026_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 23 dose ERX1595267 E-MTAB-4921:MEM027_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242734 SAMEA4071624 MEM027_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 24 dose ERX1595268 E-MTAB-4921:MEM028_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242735 SAMEA4071625 MEM028_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 25 dose ERX1595269 E-MTAB-4921:MEM029_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242736 SAMEA4071626 MEM029_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 26 dose ERX1595270 E-MTAB-4921:MEM030_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242737 SAMEA4071627 MEM030_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 27 dose ERX1595271 E-MTAB-4921:MEM031_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242738 SAMEA4071628 MEM031_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 28 dose ERX1595272 E-MTAB-4921:MEM032_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242739 SAMEA4071629 MEM032_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 29 dose ERX1595273 E-MTAB-4921:MEM033_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242740 SAMEA4071630 MEM033_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 30 dose ERX1595274 E-MTAB-4921:MEM034_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242741 SAMEA4071631 MEM034_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 31 dose ERX1595275 E-MTAB-4921:MEM035_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242742 SAMEA4071632 MEM035_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 32 dose ERX1595276 E-MTAB-4921:MEM036_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242743 SAMEA4071633 MEM036_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 33 dose ERX1595277 E-MTAB-4921:MEM037_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242744 SAMEA4071634 MEM037_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 34 dose ERX1595278 E-MTAB-4921:MEM038_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242745 SAMEA4071635 MEM038_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 35 dose ERX1595279 E-MTAB-4921:MEM039_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242746 SAMEA4071636 MEM039_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 36 dose ERX1595280 E-MTAB-4921:MEM040_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242747 SAMEA4071637 MEM040_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 37 dose ERX1595281 E-MTAB-4921:MEM041_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242748 SAMEA4071638 MEM041_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 38 dose ERX1595282 E-MTAB-4921:MEM042_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242749 SAMEA4071639 MEM042_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 39 dose ERX1595283 E-MTAB-4921:MEM043_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242750 SAMEA4071640 MEM043_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 40 dose ERX1595284 E-MTAB-4921:MEM044_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242751 SAMEA4071641 MEM044_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 41 dose ERX1595285 E-MTAB-4921:MEM045_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242752 SAMEA4071642 MEM045_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 42 dose ERX1595286 E-MTAB-4921:MEM046_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242753 SAMEA4071643 MEM046_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 43 dose ERX1595287 E-MTAB-4921:MEM047_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242754 SAMEA4071644 MEM047_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 44 dose ERX1595288 E-MTAB-4921:MEM048_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242755 SAMEA4071645 MEM048_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 45 dose ERX1595289 E-MTAB-4921:MEM049_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242756 SAMEA4071646 MEM049_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 46 dose ERX1595290 E-MTAB-4921:MEM050_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242757 SAMEA4071647 MEM050_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 47 dose ERX1595291 E-MTAB-4921:MEM051_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242758 SAMEA4071648 MEM051_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 48 dose ERX1595292 E-MTAB-4921:MEM052_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242759 SAMEA4071649 MEM052_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 49 dose ERX1595293 E-MTAB-4921:MEM053_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242760 SAMEA4071650 MEM053_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 50 dose ERX1595294 E-MTAB-4921:MEM054_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242761 SAMEA4071651 MEM054_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 51 dose ERX1595295 E-MTAB-4921:MEM055_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242762 SAMEA4071652 MEM055_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 52 dose ERX1595296 E-MTAB-4921:MEM056_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242763 SAMEA4071653 MEM056_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 53 dose ERX1595297 E-MTAB-4921:MEM057_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242764 SAMEA4071654 MEM057_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 54 dose ERX1595298 E-MTAB-4921:MEM058_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242765 SAMEA4071655 MEM058_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 55 dose ERX1595299 E-MTAB-4921:MEM059_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242766 SAMEA4071656 MEM059_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 56 dose ERX1595300 E-MTAB-4921:MEM060_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242767 SAMEA4071657 MEM060_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 57 dose ERX1595301 E-MTAB-4921:MEM061_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242768 SAMEA4071658 MEM061_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 58 dose ERX1595302 E-MTAB-4921:MEM062_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242769 SAMEA4071659 MEM062_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 59 dose ERX1595303 E-MTAB-4921:MEM065_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242770 SAMEA4071660 MEM065_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: normal disease Experimental Factor: 60 dose ERX1595304 E-MTAB-4921:MEM066_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242771 SAMEA4071661 MEM066_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: normal disease Experimental Factor: 61 dose ERX1595305 E-MTAB-4921:MEM067_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242772 SAMEA4071662 MEM067_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: normal disease Experimental Factor: 62 dose ERX1595306 E-MTAB-4921:MEM076_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242773 SAMEA4071663 MEM076_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 63 dose ERX1595307 E-MTAB-4921:MEM077_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242774 SAMEA4071664 MEM077_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: melanoma disease Experimental Factor: 64 dose ERX1595308 E-MTAB-4921:MEM078_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242775 SAMEA4071665 MEM078_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: lung carcinoma disease Experimental Factor: 65 dose ERX1595309 E-MTAB-4921:MEM090_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242776 SAMEA4071666 MEM090_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: normal disease Experimental Factor: 66 dose ERX1595310 E-MTAB-4921:MEM091_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242777 SAMEA4071667 MEM091_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: hepatocellular carcinoma disease Experimental Factor: 67 dose ERX1595311 E-MTAB-4921:MEM092_s ERP016417 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS ERS1242778 SAMEA4071668 MEM092_s WGS GENOMIC RANDOM The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA) Illumina HiSeq 2500 Experimental Factor: normal disease Experimental Factor: 68 dose